Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589–600. doi: 10.1056/NEJMra020528
George JN, et al. Syndromes of thrombotic microangiopathy. N Engl J Med 2014; 371:654–666. doi: 10.1056/NEJMra1312353
Reynolds JC, et al. Thrombotic microangiopathy after renal transplantation in the United States. Am J Kidney Dis 2003; 42:1058–1068. doi: 10.5500/wjt.v8.i5.122
Scully M, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost 2017; 15:312–322. doi: 10.1111/jth.13571
Visweswaran K, Ponticelli C, eds. Current Progress in Nephrology, 3rd ed., 2022; Chapter 10:181–197.
Palma LMP, et al. Complement in secondary thrombotic microangiopathy. Kidney Int Rep 2021; 6:11–23. doi: 10.1016/j.ekir.2020.10.009
Garg N, et al. De novo thrombotic microangiopathy after kidney transplantation. Transplant Rev (Orlando) 2018; 32:58–68. doi: 10.1016/j.trre.2017.10.001
Schwimmer J, et al. De novo thrombotic microangiopathy in renal transplant recipients: A comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy. Am J Kidney Dis 2003; 41:471–479. doi: 10.1053/ajkd.2003.50058
Java A. Peri- and post-operative evaluation and management of atypical hemolytic uremic syndrome (aHUS) in kidney transplantation. Adv Chronic Kidney Dis 2020; 27:128–137. doi: 10.1053/j.ackd.2019.11.003
Renner B, et al. Cyclosporine induces endothelial cell release of complement-activating microparticles. J Am Soc Nephrol 2013; 24:1849–1862. doi: 10.1681/ASN.2012111064
Kaufman DB, et al. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine‐associated hemolytic uremic syndrome. Transplantation 1995; 59:1737–1739. doi: 10.1097/00007890-199506270-00017
Cedric E, et al. Sirolimus‐based immunosuppression for transplant‐associated thrombotic microangiopathy. Nephrol Dial Transplant 2002; 17:1524–1526. doi: 10.1093/ndt/17.8.1524
Wu K, et al. The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. Clin Transplant 2016; 30:105–117. doi: 10.1111/ctr.12645
Satoskar AA, et al. De novo thrombotic microangiopathy in renal allograft biopsies—role of antibody-mediated rejection. Am J Transplant 2010; 10:1804–1811. doi: 10.1111/j.1600-6143.2010.03178.x
Java A, et al. The complement system in COVID-19: Friend and foe? JCI Insight 2020; 5:e140711. doi: 10.1172/jci.insight.140711
Ren Z, et al. Clinicopathologic implications of complement genetic variants in kidney transplantation. Front Med (Lausanne) 2021; 8:775280. doi: 10.3389/fmed.2021.775280